FUS1 is a novel tumor suppressor gene located in the human chromosome 3p21.3 region. We previously showed that restoration of FUS1 function in 3p21.3-deficient human non-small-cell lung cancer (NSCLC) cells significantly inhibited tumor cell growth in vitro and in vivo. In this study, we evaluated the combined effects of the tumor suppressor FUS1 and the chemotherapeutic drug cisplatin on tumor cell growth and apoptosis induction in NSCLC cells, and explored the molecular mechanism of their mutual action. Exogenous expression of FUS1 by nanoparticle-mediated gene transfer sensitized the response of NSCLC cells to cisplatin, resulting in a 4-to 6-fold increase in tumor-suppressing activity. A systemic treatment with a combination of FUS1-nanoparticles and cisplatin in a human H322 lung cancer orthotopic xenograft mouse model dramatically enhanced the therapeutic efficacy of cisplatin. We also found that the FUS1-enhanced chemosensitivity is associated with the downregulation of MDM2, accumulation of p53 and activation of the Apaf-1-dependent apoptosis pathway. Our results demonstrated an important role of FUS1 in modulating chemosensitivity of lung cancer cells, and suggested that a proper combination of molecular therapeutics such as the proapoptotic tumor suppressor FUS1 and the conventional chemotherapeutic drugs such as cisplatin may be an efficient treatment strategy for human lung cancer.
Introduction
Lung cancer is the leading cause of cancer-related death worldwide. Non-small-cell lung cancer (NSCLC) is a major form of lung cancer and the incidence of NSCLC has been increasing in the past several decades. 1 Recent advances in lung cancer biology and genetics have suggested new treatment strategies. Although the outcome is still poor, the management of locally advanced NSCLC has progressed in recent years with the use of combined therapeutic modalities. 2, 3 Over the past few years, concurrent chemotherapy and radiation therapy for advanced lung cancer have significantly improved local control and overall survival. 4, 5 However, not all tumor types may respond to such an extent to combined treatment. Thus, optimization of combinations of conventional and novel therapeutic agents may improve the outcome of treatment for lung cancer. Cisplatin (cis-diamminedichloroplatinum, CDDP), a DNA damage-inducing chemotherapeutic drug, is one of the most effective therapeutic agents for advanced NSCLC treatments. 6 Few patients, however, have a complete pathologic response. Although CDDP is established as antitumor agents for the treatment of advanced NSCLC, intrinsic or acquired resistance to the chemotherapeutic agent is frequently encountered and severely limits its therapeutic potential. 3, 5, 7, 8 Tumor suppressor genes (TSGs) on chromosome 3p play a key role in the pathogenesis of human lung cancer and other cancers. [9] [10] [11] [12] [13] FUS1 is one of novel candidate TSGs clustered in a 120-kb homozygous-deletion region in the human chromosome 3p21.3 region. 14, 15 We have previously demonstrated that the forced expression of wild-type (wt)-FUS1 significantly inhibited tumor cell growth by induction of apoptosis and alteration of cellcycle kinetics in 3p21.3-deficient NSCLC cells in vitro, and efficiently suppressed tumor growth and metastasis in mouse models of human lung cancer. 15, 16 Molecular therapy by introduction of the TSGs, such as p53, into tumors has shown the potential to restore sensitivities to chemotherapy in primary lung cancers that lack p53 function. [17] [18] [19] [20] [21] [22] [23] However, no information has been available about the combined effects of exogenous expression of FUS1 tumor suppressor with any of various chemotherapeutic drugs on tumor suppression activity. Because the exogenous expression of FUS1 exhibited a similarly potent tumor-suppressing and proapoptotic activity as that of p53 in human lung cancer, we hypothesized that FUS1 may also play a role in mediating cellular responses to chemotherapeutic drugs, and that forced expression of FUS1 in chemoresistant tumor cells may sensitize or synergize their response to treatments. To test these hypotheses, we first quantitatively analyzed the combined effects of the exogenously expressed FUS1 by N-[1-(2,3-dioleoyloxyl)propyl]-NNN-trimethylammoniummethyl sulfate (DOTAP):cholesterol (DC)-nanoparticle (DC-FUS1-nanoparticle)-mediated gene transfer and chemotherapeutic drug CDDP on tumor cell growth and apoptosis induction in NSCLC cells in vitro. Next, we explored the potential of using a combination treatment with systemic injection of FUS1-nanoparticles and i.p. injection of CDDP for enhancing antitumor efficacy and overcoming drug resistance in mouse models of human lung cancer. Finally, we analyzed the effects of the combined treatment with FUS1-nanoparticles and cisplatin on biological activities of their cellular targets in cell proliferation and apoptosis pathways, to elucidate molecular mechanisms of their actions in NSCLC cells. Our results showed that exogenously introduced expression of FUS1 by nanoparticle-mediated gene transfer sensitized the response of NSCLC cells to CDDP treatment through p53-and Apaf-1-associated apoptotic pathway. Cotreatment with FUS1-nanoparticles in combination with CDDP also enhanced tumor suppression in a human lung cancer mouse model. Our results suggested that the combination treatment by the molecular therapy of 3p21.3 TSGs with the conventional chemotherapy may be an effective approach to lung cancer therapy.
Materials and methods

Cell lines and cell culture
Six human NSCLC cell lines, HCC1171, H1437, H1299, A549, H322 and H460, were used for the experiments. The A549 cells were maintained in Ham's F12 medium supplemented with 10% fetal calf serum (FCS). The other six NSCLC cell were maintained in RPMI 1640 medium supplemented with 10% FCS and 5% glutamine. All cells were incubated in a humidified atmosphere with 5% CO 2 . All cell cultures were tested regularly for possible mycoplasma contamination.
Plasmid vectors
Recombinant plasmid vectors containing the cDNA of the wild-type FUS1 gene (wt-FUS1) and a dysfunctional myristoylation defect mutant FUS1 (mut-FUS1), respectively, were used in transfection experiments. In the mut-FUS1, the predicted myristoylation site of glycine was replaced with an alanine by site-directed mutagenesis. The plasmid vector that expresses a b-galactosidase gene (LacZ) was used as a nonspecific negative control. Construction of these recombinant plasmid vectors has been described previously. 15 Immunofluorescence staining Cells were first cultured in chamber slides and transfected with plasmid DNA for 48 h. Cells were fixed with 4% paraformaldehyde in PBS (pH 7.4) for 30 min on ice. After rinsing twice with PBS cells were permeabilized with 0.2% Triton X-100 for 10 min. For immunostaining, cells were incubated with rabbit anti-FUS1 antibody diluted in PBS containing 5% bovine serum albumin for 1 h at room temperature. FITC-labeled anti-rabbit IgGs (Chemicon, Temecula, CA, USA) were diluted 1:200 in PBS and the cells were incubated with the antibodies for 30 min. The nuclei were stained by 4,6-diamidino-2-phenylindole (DAPI) and then examined under an Eclipse E400 fluorescence microscope (Nikon, Tokyo, Japan).
Tumor cell-induced clonogenicity assay
To analyze the effect of FUS1 protein on tumor cellderived clonogenicity in vitro, we transfected H1299 cells (2 Â 10 5 ) on six-well plates with a vector expressing FUS1, using DC. H1299 cells were cotransfected with 2 mg of plasmid DNA and 1 mg of pcDNA3.1 vector (Invitrogen, Carlsbad, CA, USA) containing a neomycin-resistant gene. Untransfected cells and cells transfected with the pcDNA3.1 vector (1 mg) and 2 mg of empty vector DNA served as controls. Twenty-four hours after transfection, cells were harvested, stained with Trypan blue, counted and replated onto a 100-mm dish (1 Â 10 4 per dish) in triplicate. Cells were grown in RPMI 1640, supplemented with 10% FCS and containing 400 mg ml À1 G418, for 2 weeks. The G418-resistant colonies were counted after staining with crystal violet.
Cell viability and apoptosis assay
The cells were transfected with DC-encapsulated plasmid DNA-nanoparticles. 24 The transfection efficiency was assessed by a parallel transfection with a green fluorescent protein (GFP)-expressing plasmid vector. The transfection efficiency was in the range of 40 to 60% in those cell lines. 
Small interfering RNAs
The small interfering RNAs (siRNAs) were prepared by a transcription-based method using the Silencer siRNA construction kit (Ambion, Austin, TX, USA) according to the manufacturer's instructions. Cells were transfected with siRNA duplexes by using Oligofectamine reagent (Invitrogen Corporation, Carlsbad, CA, USA). The sequences of 21-nucleotide sense and antisense RNA were as follows: si-Apaf-1, 5
0 -AAUUGGUGCACUUUUAC GUGA-3 0 (sense) and 5 0 -AAUCACGUAAAAGUGCAC CAA-3 0 (antisense); and scramble siRNA, 5 0 -AAUG GUCCGAAUCUAGUGUUU-3 0 (sense) and 5 0 -AAAA ACACUAGAUUCGGACCA-3 0 (antisense) as a nonspecific control siRNA (siNSC).
Western blot analysis
Western blots were probed with a specific antibody against FUS1, Apaf-1, p53, MDM2, caspase-3, caspase-9 or b-actin (Cell Signaling, Beverly, MA, USA). The protein bands were detected by enhanced chemiluminescence.
Animal studies
Animal experiments were performed at the Animal Core Facility at The University of Texas MD Anderson Cancer Center. An orthotopic lung tumor xenograft mouse model of human NSCLC H322, as described previously, 24 was used to evaluate the combined effect of systemic administration of the FUS1-nanoparticles and CDDP on inhibition of tumor growth in vivo. These mice were randomly divided into five treatment groups (five mice per group) as follows: (i) LacZ; (ii) wt-FUS1; (iii) CDDP; (iv) LacZ plus CDDP and (v) wt-FUS1 plus CDDP. Orthotopic tumors are usually established on the lung or on the inner thoracic membrane 10-14 days after tumor cell inoculation. On days 10, 13 and 16 after tumor inoculation, the mice were given DC-DNA-nanoparticles by tail vein injection at a dose of 25 mg of plasmid DNA and 10 nmol DC in 100 ml of 5% dextrose in water (D5W) per mouse, alone or in combination with i.p. injection of cisplatin at a dose of 2.5 mg kg
À1
. Twelve days after the last treatment, mice were killed and the total number and total weight of intrathoracic and pleural tumors of each mouse were examined in each treatment group.
To determine FUS1 expression and apoptosis in tumors, two mice in each group were treated with the designated agents and killed 48 h later, and tumors larger than 5 mm were harvested and freshly frozen. FUS1 protein expression in frozen tumor sections was detected by anti-FUS1 antibodies (1:100) using the Vectastain kit, and examined under a light microscope. Induction of apoptosis was analyzed using an in situ cell death detection kit (Roche Molecular Biochemicals) and fluorescence imaging analysis was performed.
Statistics analysis
All in vitro experiments were performed at least twice with triplicates of samples. ANOVA and Fisher's test, or t-test were used to compare the values of the test and control samples in vitro and in vivo. Po0.05 was considered statistically significant. StatView 5.0 (Abacus Concepts Inc., Berkeley, CA, USA) and SAS (Cary, NC, USA) softwares were used for all of the statistical analyses. The interaction between FUS1 and cisplatin was analyzed with a REML (Restricted Maximum Likelihood) method using the JMP software from SAS. The significance of interaction is evaluated by paired t-test.
Results
Enhanced inhibition of tumor cell clonogenicity and growth by FUS1 and CDDP To determine whether the ectopic expression of FUS1 could enhance CDDP-mediated anticancer activities and sensitize response of tumor cells to this chemotherapeutic drug, we transiently transfected NSCLC cells with FUS1-expressing plasmid by DC-nanoparticle-mediated gene transfer and co-treated these cells with CDDP, and then analyzed the combined effects of the overexpressed FUS1 and CDDP on tumor cell growth. The expression of To further evaluate the degree of FUS1-mediated sensitivity to CDDP, we determined the changes in IC 50 values of CDDP in the NSCLC cell lines. As shown in Table 1 , the ectopic expression of wt-FUS1 sensitized NSCLC cells to CDDP treatment, resulting in a 4-to 6-fold reduction of the IC 50 value when compared with the cells co-treated with CDDP and LacZ control plasmid. Take together, these results provided biological evidence that FUS1 is involved in CDDP-mediated cytotoxicity and modulates tumor cell sensitivity to the chemotherapeutic drug. The NH 2 -terminal myristoylation of the FUS1 protein is essential for FUS1-mediated tumor suppression. 15 We found that transfection of NSCLC cell lines with a myristoylation-defect mutant FUS1 plasmid (mt-FUS1), in which the expression of mut-FUS1 protein was confirmed by western blot (result not shown), in combination with CDDP treatment resulted in an attenuated apoptosis induction in comparison with those co-treated with wt-FUS1-nanoparticles and CDDP (Figure 2a) . Consistent with our previous results, treatment with mt-FUS1-nanoparticles alone did not induce apoptosis. These findings confirmed the importance of myristoylation in the antitumor activity of FUS1 and indicated that the specificity of wt-FUS1 in sensitizing NSCLC cells to chemotherapy by induction of apoptosis.
Activation of caspases is an important event in apoptosis-signaling pathway. To determine whether the enhanced apoptosis induced by combination of FUS1-nanoparticles and chemotherapy is related to the increased activation of caspases, we next analyzed the combined effects of the exogenously expressed FUS1 and CDDP treatment on activities of two key caspases, caspase-3 and caspase-9, by western blotting assay in NSCLC cells treated with FUS1-nanoparticles alone or in combination with CDDP at a dose level of IC 50 . The cells transfected with LacZ were used as negative controls. Activities of both caspase-3 and caspase-9 were clearly enhanced in the cells co-treated with wt-FUS1-nanoparticle and CDDP, compared with the cells treated with either agent alone or negative controls, as indicated by the increased intensity in the cleaved bands (p19 for caspase-3; p37 and p17 for caspase-9) from pro-proteins on the western blot (Figure 2b ). By contrast, no increased activities of caspases were observed in cells co-treated with mt-FUS1-nanoparticles and CDDP. These results are consistent with our above observations of apoptosis induction and suggest that the enhanced induction of apoptosis by wt-FUS1 is mediated by enhanced activation of caspase cascades.
Enhanced tumor growth inhibition by systemic treatment with FUS1-nanoparticles and CDDP in vivo To determine whether the FUS1-mediated increase in sensitivity to chemotherapy observed in vitro could be reproduced in vivo, and to explore the potential of FUS1 as a novel molecular therapeutic agent for more effectively modulating tumor cell response to chemotherapeutic drugs, we analyzed the therapeutic efficacy and induction of apoptosis of systemic treatment with i.v. injection of wt-FUS1-nanoparticles and i.p. injection of CDDP in human H322 orthotopic lung cancer mouse models. Consistent with the results in vitro, systemic administration of wt-FUS-nanoparticles alone for a total dose of 75 mg of DNA/mouse inhibited tumor growth (Figure 3a) , resulting in a reduction of more than 45% (Po0.005) in total tumor numbers and fresh tumor weight (Figure 3b ). Treatment with CDDP at a dose of 2.5 mg kg À1 body weight alone or in combination with LacZ control vector at a dose of 25 mg DNA/mouse per injection for three times, caused a less inhibition of tumor growth than that treated with wt-FUS1-nanoparticles alone in this CDDP-resistant lung tumor mouse model. However, a combination treatment with wt-FUS1-nanoparticles and CDDP dramatically inhibited both tumor formation and growth in the H322 orthotopic lung tumor model (Figure 3a) . A synergistic inhibition in both the total fresh tumor weights and the total tumor numbers was observed in mice treated with three injections of wt-FUS1-nanoparticles and CDDP together at same doses as each agent given alone, with a more than 90% of total tumor reduction, compared with those treated with the LacZ alone or LacZ þ CDDP-treated control groups (Po0.005; Figure 3b ). These results were consistent with those obtained in vitro.
To evaluate the biological action of systemic treatments with wt-FUS1-nanoparticle and CDDP in tumors in mice, we also analyzed the induction of apoptosis by TUNEL staining with an in situ cell death detection kit in flashfrozen tumor tissue samples prepared from H322 tumorbearing mice (Figure 3c ). Induction of apoptosis in the tumors was detected in mice treated with wt-FUS1-nanoparticles or CDDP alone. Much higher apoptosis induction was detected in tumors treated with wt-FUS1-nanoparticles (17.7%) than in those treated with CDDP alone (5.1%) or with LacZ control (1.5%). However, a synergistic induction of apoptosis (45.8%) was observed in tumors co-treated with wt-FUS1-nanoparticles and CDDP compared with those treated with either agent alone (Po0.005) or with CDDP þ LacZ (P ¼ 0.005), as indicated by TUNEL staining (Figure 3c ). These in vivo results were consistent with those observed in vitro.
Increased accumulation of p53, inhibition of MDM2 and activation of Apaf-1 by FUS1 and CDDP The p53 protein level is believed to be vital in mediating various apoptotic responses driven by antitumor agents. The cellular response to DNA-damaging agents includes both increased p53 protein accumulation and increased p53 activity. 25 To evaluate whether the enhanced tumorsuppressing activity by combination of FUS1-nanoparticles and CDDP is associated with accumulation of p53 proteins, we analyzed changes in the levels of endogenous p53 proteins in wild-type p53-bearing NSCLC cell lines A549 and H460 by western blot (Figure 4a ). An elevated level of endogenous p53 proteins was detected in cells transfected with wt-FUS1-nanoparticles or treated with CDDP alone in both A549 and H460 cells. Moreover, a dramatically increased accumulation of p53 proteins was observed in these cells treated with a combination of wt-FUS1-nanoparticles with CDDP, but no changes in the level of endogenous p53 proteins were detected in those cells treated with a combination of mutant FUS1 (mt-FUS1)-nanoparticles with CDDP, compared with those treated by CDDP alone (Figure 4a) . Furthermore, we compared the effect of FUS1 and CDDP on the accumulation of exogenous p53 in p53-negative H1299 and wt-p53-positive H460 cells by cotransfection with wt-p53 and wt-FUS1-nanoparticles in the absence and presence of CDDP. Coexpression of p53 and wt-FUS1, but not mt-FUS1, markedly increased the levels of exogenous p53 proteins in both H1299 and H460 cells (Figure 4b ). These results suggest that the enhanced antitumor activity of CDDP by FUS1 may be mediated by a FUS1-facilitated accumulation or stabilization of both endogenous and exogenous p53 proteins in NSCLC cells. Downregulation of MDM2 expression plays an important role in stabilizing p53 and enhancing p53-mediated apoptosis. To determine whether the enhanced antitumor activity by wt-FUS1 and CDDP combination is also implicated in the regulation of MDM2 expression, we analyzed the MDM2 protein levels by western blot in p53-positive A549 and H460, or p53-negative H1299 cells. A dramatic decrease of the 90-kDa MDM2 protein was detected in the A549 and H460 cells transfected with wt-FUS1-nanoparticles, but not with mt-FUS1-nanoparticles, in the absence or presence of CDDP (Figure 4a) . Coexpression of wt-FUS1 and p53 in combination with CDDP also attenuated MDM2 protein levels in both p53-deficient H1299 and p53-positive H460 cells (Figure 4b) . These results suggest that the enhanced effect of wt-FUS1
and CDDP on tumor suppression may also be achieved through the wt-FUS1-mediated downregulation of MDM2 expression in these NSCLC cells.
The activation of the Apaf-1-dependent pathway plays a key role in mitochondrial-and p53-associated apoptosis by various antitumor agents. To test whether the Apaf-1 signaling pathway is also involved in the FUS1 and CDDP-mediated antitumor activity, we studied the mutual effects of these two agents on the regulation of Apaf-1 gene expression in H1299, A549, and H460 cells by western blot. Overexpression of wt-FUS1, but not myristoylation-defect mutant FUS1 (mt-FUS1), in CDDP-treated NSCLC cells resulted in an increase in the amount of Apaf-1 protein in p53-positive A549 and H460 cells (Figure 4a ). The coexpression of p53 with wt-FUS1, but not with mt-FUS1, in combination with CDDP also increased levels of Apaf-1 proteins in both p53-deficient H1299 cells and p53-positive H460 cells (Figure 4b) .
To further confirm the involvement of Apaf-1-dependent apoptotic pathway in the FUS1-mediated enhancement of chemosensitization, we determined the effects of the Apaf-1-specific siRNA on Apaf-1 expression and apoptosis induction in H1299 and H460 cells treated with FUS1-nanoparticles and CDDP (Figure 4c ). Inhibition of Apaf-1 protein expression was detected by western blotting in both H1299 and H460 cells treated by the Apaf-1-specific siRNA (siApaf-1) compared with those treated with the scrambled nonspecific control siRNA (siNSC). We also found that treatment with siApaf-1 inhibited apoptosis induction in both H1299 and H460 cells co-treated with CDDP, p53 and wt-FUS1-nanoparticles, independent of the endogenous p53 expression, as shown by TUNEL assay with flow cytometry (Figure 4c) . Together, these results suggest that the FUS1-enhanced antitumor activity of CDDP may also be achieved by FUS1-mediated activation of the Apaf-1-associated apoptosis pathway in the presence or absence of endogenous p53 expression. After 72 h, cells were harvested and analyzed for apoptosis by TUNEL assay with fluorescence-activated cell sorter. The experiments were repeated at least three times, and error bars represent standard errors of the mean. CDDP, cis-diamminedichloroplatinum; NSCLC, non-small-cell lung cancer; siRNA, small interfering RNA; TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP nickend labeling.
Discussion
In this study, we showed that treatment with wt-FUS1-nanoparticle in combination with chemotherapeutic drug CDDP dramatically inhibited tumor cell clonogenicity and growth, and induced apoptosis in vitro. We found that the exogenously introduced expression of FUS1 sensitized response of lung cancer cells to CDDP treatment. We also demonstrated that the FUS1-enhanced sensitivity to CDDP chemotherapy observed in vitro could be reproduced in vivo. Co-treatment with wt-FUS1-nanoparticles and CDDP synergistically suppressed tumor growth and induced apoptosis in human lung cancer orthotopic tumor xenograft mouse model. To our knowledge, this is the first report regarding the combined introduction of FUS1 tumor suppressor and the conventional chemotherapeutic agents in human NSCLC cells. Cellular responses to chemotherapeutic drugs are frequently attributed to the apoptosis and cytotoxicity induced by such agents. 7 Because apoptosis is a genetically programmed cellular response to environmental stresses or stimuli, mutations in apoptotic pathways and the decreased susceptibility to apoptosis have been shown to be associated with cellular resistance to chemotherapeutic drugs and radiation treatment in various human cancers including lung cancer. [25] [26] [27] [28] [29] [30] [31] We previously showed that exogenous expression of FUS1 in FUS1-deficient NSCLC cells might effectively inhibit tumor cell growth and induce apoptosis in vitro and in vivo. 13, 15 The overexpression of FUS1 in CDDP-treated NSCLC cells may overcome the cellular resistance and enhance the cellular response to the chemotherapy by facilitating the drug-induced apoptosis and other cell dead pathways. Because most NSCLC tumors and tumor-derived cell lines are deficient in FUS1 protein expression or posttranslational myristoylation modification, 14, 15 this combination treatment approach with proapoptotic tumor suppressor FUS1 and conventional chemotherapeutic agents may provide an excellent opportunity to modulate chemosensitivity of lung cancer cells.
We found that the FUS1-enhanced sensitivity of NSCLC cells to CDDP therapy is associated with the FUS1-mediated accumulation of p53 protein. The p53 is a central regulator of cellular responses to stress. A low level of latent p53 is present in normal cells, and is stabilized and activated through post-transcriptional modification, which can lead to cell cycle arrest, DNA repair or apoptosis. Activation of p53 by CDDP-induced DNA damage has been reported to have various effects on cellular sensitivity to CDDP. 32 Chemotherapy resistance has been associated with decreased susceptibility to apoptosis, introducing the possibility that cell death determinants may influence the outcome of treatment. Recent study reported that cisplatin-induced extracellular signal-regulated kinase activation acts as an upstream regulator of p53 protein accumulation following cisplatin DNA damage. 33 However, the involvement of p53 accumulation in FUS1-mediated enhancement of antitumor activity of chemotherapeutic drugs has not been reported in lung cancer cells. Our findings of the increased accumulation of the endogenous or the exogenous of p53 proteins by FUS1-nanoparticles in combination with CDDP revealed a novel signaling pathway by which FUS1 sensitizes lung cancer cells to chemotherapy.
MDM2, an antagonist of p53, is believed to normally operate in a feedback loop to inhibit p53 and alleviate cell cycle arrest, thus facilitating cell cycle re-entry after DNA damage and repair. [34] [35] [36] [37] [38] There is substantial genetic evidence that MDM2 may downregulate p53 activity in normal cells even in the absence of exogenous DNA damage. 39 It has been shown that MDM2 interacts directly with p53 in the NH 2 -terminal domains. As a result of this interaction, MDM2 directly targets p53 for degradation by proteolysis and blocks the tumor suppression activity of p53. 38, 40 It has thus become clear that one way to stabilize and activate p53 in cells is by interrupting the interaction of MDM2 and p53. 7 In this study, we observed a significant reduction of MDM2 proteins in NSCLC cells transfected with wt-FUS1 or wt-FUS1 plus p53-nanoparticles, in the absence or presence of CDDP. These results suggest that the overexpression of wt-FUS1 may interrupt the association of MDM2 with p53 and, subsequently, block the MDM2-medaited p53 degradation. Thus, the FUS1-and CDDP-enhanced tumor suppression by a facilitated apoptosis induction may be closely associated with the FUS1-mediated downregulation of MDM2 in these NSCLC cells.
We also demonstrated that exogenous expression of FUS1 upregulates Apaf-1 expression and showed that Apaf-1 is essential for FUS1-mediated chemosensitivities, by gene expression interference assay using Apaf-1-genespecific siRNAs. Apaf-1 is a key factor in the mitochondrial apoptotic pathway and a transcriptional target of p53. Although p53 induces the activity of several proapoptotic genes other than Apaf-1, the expression of Apaf-1 has been shown to be essential for p53-dependent apoptosis. [41] [42] [43] [44] Overexpression of Apaf-1 has also been shown to partially reverse the acquired CDDP resistance by facilitating apoptosis in HeLa cells. 45 We have found that FUS1 protein could directly interact with Apaf-1 protein and regulate the activity of Apaf-1 in NSCLC cells (details will be published elsewhere). Taken together, our data suggest an essential role of FUS1 in modulating CDDP-induced tumor suppression and cellular resistance by dynamically regulating Apaf-1-associated cell death pathway in tumor cells.
In summary, we demonstrated that a treatment with FUS1-nanoparticles in combination with CDDP dramatically inhibited tumor cell clonogenicity and growth, and induced apoptosis in vitro and in vivo. The enhanced sensitivity of NSCLC cells to CDDP by FUS1 is associated with the FUS1-mediated accumulation of p53, downregulation of MDM2 and activation of the Apaf-1-dependent apoptosis pathway. Our findings therefore provide new insights into the molecular mechanisms of the FUS1-mediated tumor suppression and suggest that a combination with the molecular therapy of novel TSGs such as FUS1 and the conventional chemotherapy such platinum drugs may be an effective treatment strategy for human lung cancer and other cancers.
